ProQR Therapeutics (PRQR) Competitors $3.67 +0.07 (+1.94%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends PRQR vs. ANIP, ARDX, APLT, AVDL, ZYME, SEPN, COGT, BCAX, BCYC, and COLLShould you be buying ProQR Therapeutics stock or one of its competitors? The main competitors of ProQR Therapeutics include ANI Pharmaceuticals (ANIP), Ardelyx (ARDX), Applied Therapeutics (APLT), Avadel Pharmaceuticals (AVDL), Zymeworks (ZYME), Septerna (SEPN), Cogent Biosciences (COGT), Bicara Therapeutics (BCAX), Bicycle Therapeutics (BCYC), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical products" industry. ProQR Therapeutics vs. ANI Pharmaceuticals Ardelyx Applied Therapeutics Avadel Pharmaceuticals Zymeworks Septerna Cogent Biosciences Bicara Therapeutics Bicycle Therapeutics Collegium Pharmaceutical ANI Pharmaceuticals (NASDAQ:ANIP) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, community ranking, dividends, valuation, profitability, earnings, institutional ownership and media sentiment. Which has higher valuation and earnings, ANIP or PRQR? ANI Pharmaceuticals has higher revenue and earnings than ProQR Therapeutics. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioANI Pharmaceuticals$555.46M2.09$18.78M-$0.55-100.18ProQR Therapeutics$7.05M42.52-$30.43M-$0.32-11.47 Does the MarketBeat Community favor ANIP or PRQR? ANI Pharmaceuticals received 104 more outperform votes than ProQR Therapeutics when rated by MarketBeat users. Likewise, 64.48% of users gave ANI Pharmaceuticals an outperform vote while only 61.54% of users gave ProQR Therapeutics an outperform vote. CompanyUnderperformOutperformANI PharmaceuticalsOutperform Votes43264.48% Underperform Votes23835.52% ProQR TherapeuticsOutperform Votes32861.54% Underperform Votes20538.46% Do analysts prefer ANIP or PRQR? ANI Pharmaceuticals currently has a consensus price target of $77.33, suggesting a potential upside of 40.35%. ProQR Therapeutics has a consensus price target of $7.13, suggesting a potential upside of 94.14%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe ProQR Therapeutics is more favorable than ANI Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ANI Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83ProQR Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Which has more risk and volatility, ANIP or PRQR? ANI Pharmaceuticals has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500. Do institutionals & insiders have more ownership in ANIP or PRQR? 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 12.7% of ANI Pharmaceuticals shares are owned by company insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is ANIP or PRQR more profitable? ANI Pharmaceuticals has a net margin of -1.28% compared to ProQR Therapeutics' net margin of -134.31%. ANI Pharmaceuticals' return on equity of 15.87% beat ProQR Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ANI Pharmaceuticals-1.28% 15.87% 6.88% ProQR Therapeutics -134.31%-71.58%-19.70% Does the media prefer ANIP or PRQR? In the previous week, ANI Pharmaceuticals had 1 more articles in the media than ProQR Therapeutics. MarketBeat recorded 4 mentions for ANI Pharmaceuticals and 3 mentions for ProQR Therapeutics. ANI Pharmaceuticals' average media sentiment score of 1.23 beat ProQR Therapeutics' score of -0.29 indicating that ANI Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ProQR Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryANI Pharmaceuticals beats ProQR Therapeutics on 13 of the 19 factors compared between the two stocks. Ad Wyatt Investment ResearchMy #1 Pre IPO Trade for 2025 – NAME and TICKEROne tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRQR vs. The Competition Export to ExcelMetricProQR TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$294.05M$6.48B$5.05B$8.87BDividend YieldN/A8.12%4.97%4.06%P/E Ratio-11.475.5697.3414.18Price / Sales42.52348.141,218.4289.42Price / CashN/A22.1533.5132.79Price / Book10.797.885.805.12Net Income-$30.43M$153.61M$119.07M$225.99M7 Day Performance-7.09%-2.00%-1.83%-1.32%1 Month Performance-9.38%-7.47%-3.64%0.60%1 Year Performance158.45%31.80%31.62%26.23% ProQR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRQRProQR Therapeutics2.0484 of 5 stars$3.67+1.9%$7.13+94.1%+143.0%$294.05M$7.05M-11.47180ANIPANI Pharmaceuticals4.4257 of 5 stars$55.10-1.1%$77.33+40.4%+7.4%$1.17B$555.46M-100.18642Positive NewsARDXArdelyx4.0014 of 5 stars$4.92+2.7%$10.42+111.7%+12.3%$1.17B$124.46M-16.40267Short Interest ↑APLTApplied Therapeutics4.3431 of 5 stars$9.43+5.6%$12.50+32.6%+373.9%$1.10B$9.99M-5.8330AVDLAvadel Pharmaceuticals2.3424 of 5 stars$10.75+0.3%$24.43+127.2%-7.5%$1.03B$27.96M0.00154Short Interest ↓ZYMEZymeworks2.4008 of 5 stars$14.55-1.5%$19.00+30.6%+74.0%$1.02B$76.01M0.00290SEPNSepternaN/A$22.50-7.0%$43.67+94.1%N/A$1.02BN/A0.00N/AAnalyst ForecastNews CoverageGap UpCOGTCogent Biosciences2.866 of 5 stars$9.08+0.2%$14.83+63.4%+20.6%$1.00BN/A0.0080Analyst RevisionBCAXBicara Therapeutics3.1692 of 5 stars$18.38-4.9%$43.33+135.8%N/A$1.00BN/A0.0032Analyst RevisionBCYCBicycle Therapeutics2.8475 of 5 stars$20.36-0.6%$40.13+97.1%+49.4%$968.12M$26.98M-6.19240Analyst RevisionCOLLCollegium Pharmaceutical3.9744 of 5 stars$30.00+0.8%$42.60+42.0%+17.2%$967.50M$566.77M12.93210 Related Companies and Tools Related Companies ANI Pharmaceuticals Competitors Ardelyx Competitors Applied Therapeutics Competitors Avadel Pharmaceuticals Competitors Zymeworks Competitors Septerna Competitors Cogent Biosciences Competitors Bicara Therapeutics Competitors Bicycle Therapeutics Competitors Collegium Pharmaceutical Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PRQR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share ProQR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRQR Stock Alerts